Assyro AI

FDA Orange Book · active-ingredient family

Ketoprofen

Ketoprofen is approved as 5 brand and 10 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:ORUDIS KT · NDA 020429

5

Brand (NDA)

10

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, capsule, extended release, film, tablet

ProductApplicantApplicationTEApproved
ORUDIS KTRLDWYETH CONSNDA 020429Oct 06, 1995
ORUVAILRLD×3WYETH PHARMS INCNDA 019816Feb 08, 1995
ORUDISRLD×3WYETH AYERSTNDA 018754Jul 31, 1987
NEXCEDENOVARTISNDA 022470Nov 25, 2009
ACTRONBAYERNDA 020499Oct 06, 1995

Generic (ANDA) products (10)

ProductApplicantApplicationTEApproved
KETOPROFEN×3MYLANANDA 075679Feb 20, 2002
KETOPROFENPERRIGOANDA 075364Feb 07, 2002
KETOPROFEN×3ACTAVIS LABS FL INCANDA 075270Mar 24, 1999
KETOPROFENALKERMES GAINESVILLEANDA 074879Dec 10, 1997
KETOPROFEN×2RISINGANDA 074035Dec 31, 1996
KETOPROFEN×2RISINGANDA 074024Dec 29, 1995
KETOPROFEN×3MISEMERANDA 074014Jan 29, 1993
KETOPROFENTEVAANDA 073515Dec 22, 1992
KETOPROFENTEVAANDA 073516ABDec 22, 1992
KETOPROFENTEVAANDA 073517Dec 22, 1992

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Ketoprofen — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.